Xbrane Biopharma: SEK240m directed issue with positive implications - Redeye
Bildkälla: Stockfoto

Xbrane Biopharma: SEK240m directed issue with positive implications - Redeye

Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional and industrial capital. The net proceeds bridge the funding gap, and we view this as a strong outcome among the possible financing scenarios - adjusting our base case accordingly.

Redeye comments on Xbrane following its SEK240m directed share issue targeting both institutional and industrial capital. The net proceeds bridge the funding gap, and we view this as a strong outcome among the possible financing scenarios - adjusting our base case accordingly.
Börsvärldens nyhetsbrev